KalraS., 2013.Glucagon-like peptide-1 receptors agonists (GLP1 RA),J Pak Med Assoc 63 1312 -5
IntarciaAnnounces, 2017.Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results,Cited on 30 October -
Delpor, 2017.Awarded $1.5 million NIH Grant for Exenatide Implant for the Treatment of Type 2 Diabetes,id=1028. Cited on 30 October -
2017.Current drug delivery limitations,Cited on 30 October -
Applications, 2017.,Cited on 30 October -
TheMedici Drug Delivery System, 2017.,Cited on 30 October -
HenryRR,LoganD,AlessiT,BaronMA, .A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes., -
2013.Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes,Diabetes care 36 2559 -65
2014.Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes,J Diabetes Complications 28 393 -8
HenryR,RosenstockJ,McCarthyJF,CarlsG,AlessiT,YeeJ,BaronM, 2018.Treatment Satisfaction with ITCA 650, a Novel Drug?device Delivering Continuous Exenatide versus Twice?Daily Injections of Exenatide in Type 2 Diabetics on Metformin,Diabetes Obes Metab 10 638 -645